Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474752 | 0.81 | LDHA (0.53) | LDHAALDH1A1GAA | |
| SCHEMBL6573972 | 0.80 | LDHA (0.58) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL10938132 | 0.77 | LDHA (0.54) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL490731 | 0.72 | LDHA (1.00) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL6575924 | 0.72 | LDHA (0.49) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL9383093 | 0.71 | LDHA (0.67) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL11911907 | 0.71 | LDHA (0.78) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL2335571 | 0.70 | LDHA (0.54) | LDHACA2MMP1MAPTALDH1A1 | |
| SCHEMBL7513442 | 0.70 | LDHA (0.76) | LDHACA2MMP1ALOX15ALOX12 | |
| SCHEMBL9781691 | 0.70 | LDHA (0.76) | LDHACA2MMP1ALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2359819-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | Temple University - Of The Commonwealth System of Higher Education (US) | 2011-08-24 | — | — | EP | disclosed |
| US-6642410-B2 | Useful as antiproliferative agents, including, for example, anticancer agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-11-04 | — | — | US | disclosed |
| EP-1305015-A4 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2003-05-21 | — | — | EP | disclosed |
| EP-1305015-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | REDDY E PREMKUMAR (US) | 2003-02-20 | — | — | US | disclosed |
| US-6486210-B2 | SUCH AS ENANTIOMORPHS OF 4-FLUOROSTYRYL-2,3,4,5,6-PENTAFLUOROBENZYLSULFONE; ANTIPROLIFERATIVE/ANTICANCER AGENTS | Temple University—Of the Commonwealth System of Higher Education | 2002-11-26 | — | — | US | disclosed |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-08-22 | — | — | US | disclosed |
| WO-2001078712-A1 | SUBSTITUTED STYRYL BENZYLSULFONES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030036536-A1 | Useful as antiproliferative agents, including, for example, anticancer agents | MKI67, MCL1, CCNA1 | LDHA 2927/4885CA2 3943/4885MMP1 2945/4885 |
| US-20020115643-A1 | Substituted styryl benzylsulfones for treating proliferative disorders | HCCS, CCNO, HRAS | LDHA 2202/4885CA2 1209/4885MMP1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.